elegantly demonstrated that mouse IL-15 modification confers tumor vasculature-targeted CAR-T cells with enhanced effector functions, engraftment, and tumor microenvironment (TME) reprogramming capability, leading to better tumor control in immunocompetent mice (19), further providing a robust rationale for developing IL-15-expressing CAR-T cells to improve the therapeutic activity of CAR-T cells in solid tumors. Here, IL15 is linked to neoplasm.